NCT06454383View on ClinicalTrials.gov

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

November 13, 2026

Study Completion Date

November 13, 2026

Conditions
Advanced Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Ductal Adenocarcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Cholestyramine

Given PO

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Diagnostic Imaging

Undergo imaging scans

DRUG

Gemcitabine

Given IV

DRUG

Leflunomide

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER